文献速递免疫规划传染病防控与疫情报告

曼尼托巴省1992-2015年百日咳疫苗有效性与保护持续时间的巢式病例对照研究

A nested case-control study measuring pertussis vaccine effectiveness and duration of protection in Manitoba, Canada, 1992-2015: A Canadian Immunization Research Network Study.
PubMed 文献 · Vaccine · 2019-09-26

该研究利用曼尼托巴省免疫和传染病登记数据,采用巢式病例对照设计,分析1992年4月1日至2015年3月31日实验室确诊百日咳病例并匹配对照,评估全细胞和无细胞百日咳疫苗的有效性及保护持续时间。结果显示含aP疫苗调整VE为85%(95%CI:74-91%),末次接种后1-3年VE为89%(66-96%);含wP疫苗在1994-1995年大流行期间调整VE为-15%(-91-31%),非流行年为35%(-26-66%)。

要点

  • 含aP疫苗调整VE为85%(95%CI:74-91%),末次接种后1-3年VE为89%(66-96%)。
  • 含wP疫苗在1994-1995年大流行期间VE为-15%(-91-31%),非流行年为35%(-26-66%)。
  • 大流行期间VE较低,提示估算百日咳VE时应单独分析流行期。

核心结论

  • 含aP疫苗自引入曼尼托巴省以来在预防百日咳方面有效。
  • 大流行期间VE较低,估算百日咳VE随时间变化时应单独分析流行期。

研究设计与样本

  • 采用巢式病例对照设计,病例为1992年4月1日至2015年3月31日曼尼托巴省实验室确诊百日咳个体。
  • 按年龄、性别、地理和病例医生或就诊次数匹配最多5名基于人群的对照。
  • 使用条件logistic回归估算含wP和含aP百日咳疫苗的VE,并通过末次接种后时间评估保护持续时间。

主要发现

  • 共纳入534例合格病例和2614名对照进行分析。
  • 含aP疫苗调整VE为85%(95%CI:74-91%)。
  • 末次接种后1至3年VE为89%(66-96%)。
  • 含wP疫苗在1994和1995年大流行期间调整VE为-15%(-91-31%),非流行年为35%(-26-66%)。

关键数值与推荐

  • 含aP疫苗调整VE为85%(95%CI:74-91%)。
  • 末次接种后1至3年VE为89%(95%CI:66-96%)。
  • 含wP疫苗大流行期间调整VE为-15%(95%CI:-91-31%),非流行年为35%(95%CI:-26-66%)。

临床怎么用

  • 在评估百日咳疫苗有效性时,应分别分析流行期与非流行期的数据。
  • 含aP疫苗在末次接种后1至3年仍显示较高保护效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pertussis persists in Manitoba despite the universal availability of pertussis vaccines. Recent cases have included previously vaccinated individuals, raising concerns about declining vaccine effectiveness (VE). We measured pertussis VE and duration of protection using Manitoba's provincial immunization and communicable disease registries. METHODS: Using a nested case-control design, individuals with laboratory-confirmed pertussis in Manitoba diagnosed between April 1, 1992, and March 31, 2015, were matched to up to five population-based controls on age, gender, geography, and case physician or number of physician visits. Conditional logistic regression was used to estimate VE against pertussis for both the whole-cell (wP) and acellular (aP) pertussis vaccines. Duration of protection was assessed using time since last dose. RESULTS: Data on 534 eligible cases and 2614 controls were available for analysis. The adjusted VE estimate for aP-containing vaccines was 85% (95%CI: 74-91%); VE was 89% (66-96%) one to three years after the last vaccination. The adjusted VE of wP-containing vaccines was -15% (-91-31%) during a large outbreak in 1994 and 1995 compared to 35% (-26-66%) during non-outbreak years. CONCLUSIONS: Our estimates suggest that the aP vaccine was effective in preventing pertussis since its introduction in Manitoba. VE was lower during a large outbreak, highlighting the importance of separately analyzing outbreak periods when estimating pertussis VE over time.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wilkinson K, Righolt CH, Kwong JC, et al. A nested case-control study measuring pertussis vaccine effectiveness and duration of protection in Manitoba, Canada, 1992-2015: A Canadian Immunization Research Network Study. Vaccine. 2019. PMID: 31564453. doi:10.1016/j.vaccine.2019.09.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。